According to Haoyuan Pharmaceutical's announcement, Yaoyuan Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, underwent pre-approval inspection by the US FDA from June 22 to 26, 2026, and recently received an on-site inspection report confirming that it passed the inspection with zero defects. This is the first time that the formulation production base has passed the US FDA inspection, which will help the company expand the US market and have a positive impact on business performance and international competitiveness.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.